MapLight Therapeutics MPLT
NASDAQ MPLT
$7.44 +0.16 (+2.20%)
At close: Nov 10, 2026 · 4:00 PM EST

MapLight Therapeutics (MPLT) Current Deferred Revenue (2024 - 2025)

Updated

MapLight Therapeutics (MPLT) reported Current Deferred Revenue of $1.21 million for Q3 2025.

Analysis

MapLight Therapeutics (MPLT) Current Deferred Revenue (2024 - 2025) Analysis & Trends

At the end of FY2024, MapLight Therapeutics posted Current Deferred Revenue of $3.24 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 MapLight Therapeutics 340.28 Mn 340.28 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 1.21 Mn
Dec 31, 2024 3.24 Mn
API Access

MapLight Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=MPLT&period=max&api_key=YOUR_API_KEY